This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, has been featured in TheStreet.com, Genetic Engineering & Biotechnology News and Drug Discovery News during the month of February.
On February 14, Tonix CEO Seth Lederman, M.D. spoke to reporter Gregg Greenberg in a video segment on TheStreet.com titled "Tonix CEO: Investors Seeing Value in Reformulation Strategy," during which Dr. Lederman discussed the company's current activities and future plans. To view the video segment in its entirety, please visit the following link:
The February 15 issue of Genetic Engineering & Biotechnology News featured a corporate profile of the company titled "Tonix Targets Reformulation to Create Value," highlighting the company's drug reformulation and repurposing strategy. To read the article in its entirety, please visit the following link:
The February issue of Drug Discovery News featured the first half of a two-part print interview with Dr. Lederman titled "Seth Lederman: Looking to past medications for the future," in which he outlined the company's drug repurposing strategy. To read the article in its entirety, please visit the following link:
http://ddn-news.com/index.php?newsarticle=8124About Tonix Pharmaceuticals Holding Corp.
Tonix is developing innovative prescription medications to treat fibromyalgia, post-traumatic stress disorder (PTSD), and tension headache, all characterized by inadequate treatment options, dissatisfaction expressed among patients and physicians, and significant expense burden. Tonix leverages the established human safety and pharmacokinetics of known drugs and, through a directed process of repurposing and reformulation, creates novel products to address important problems that often lack validated animal models or defined molecular targets. Tonix is currently enrolling patients into the first anticipated pivotal trial of TNX-102 SL in fibromyalgia, the BESTFIT trial (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy). Tonix expects to begin clinical development of TNX-102 SL in PTSD in the third quarter of 2014. With TNX-102 SL, Tonix approaches the treatment of people suffering from fibromyalgia and PTSD by targeting their inability to obtain restorative sleep. TNX-201 is in development for the treatment of tension-type headache. To learn more, please visit
Forward-Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the amended Annual Report on Form 10-K/A filed with the SEC on November 22, 2013 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
CONTACT: Tonix Pharmaceuticals Holding Corp.
Chief Financial Officer
(212) 980-9155 x104
Dian Griesel Int'l
Susan Forman or Laura Radocaj